HEALTH AND SAFETY

» Drug, Devices, and Supplements

» Physician Accountability

» Consumer Product Safety

» Worker Safety

» Health Care Delivery

» Auto and Truck Safety

» Global Access to Medicines

» Infant Formula Marketing

 

Read our outrages

If you're not outraged,
you're not paying attention!


Read what Public Citizen has to say about the biggest blunders and outrageous offenses in the world of public health, published monthly in Health Letter.

Avandia

July 2013

Sidney M. Wolfe, M.D.

The diabetes drug rosiglitazone (Avandia) was removed from the European market in 2010 by the European Medicines Agency (EMA) due to the cardiovascular risks the drug posed. So why is it that thousands of Americans (132,000 since 2010) continued to be prescribed the dangerous medication, likely resulting in hundreds or more serious, even fatal, adverse reactions, including heart failure and heart attacks?

The “reason,” if it can be called reasonable, was that although both authorities had access to the same safety studies, the Food and Drug Administration (FDA) and the EMA reached very different conclusions in September 2010 regarding the fate of this once top-selling diabetes drug. The EMA concluded that new data support the drug’s posing an increased cardiovascular risk. Since that agency “could not identify additional measures that would reduce the cardiovascular risk,” they “concluded that the benefits of rosiglitazone no longer outweigh its risks and recommended the suspension of the marketing authorisation of the medicine.” Furthermore, the EMA was so concerned about Avandia’s dangers that when it banned the drug, it stated that the only way it could ever be marketed again was if the manufacturer could “provide convincing data to identify a group of patients in whom the benefits of the medicines outweigh their risks.”

After a July 2010 advisory committee meeting, the FDA, in contrast, decided not to ban the drug but to institute a risk evaluation and management strategy (REMS) to limit the use of the drug to those the agency “believed” could benefit. The patient-reckless conclusion was not to approve a REMS until May 2011. (It was not fully in place until six months later). However, there has never been any evidence that those getting the drug in this country have been patients for whom the benefits of the medicines outweighed their risks.

Once again, instead of banning a drug — as recommended by 12 FDA advisory committee members —because it lacks unique benefits but poses unique risks, the FDA has hidden behind a REMS program that has reduced the number of people using the drug to 2,400 in 2012. Unfortunately, the 132,000 people who used Avandia in the U.S. since 2010 represent hundreds of preventable injuries and deaths.

REMS should be reserved for drugs that need to remain available. By no stretch of the imagination is Avandia such a drug. Ask the EMA. Unfortunately, the FDA is considering relaxing its restrictions. We continue to advise patients not to use this dangerous drug.

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.